公开(公告)号：US20240299439A1

公开(公告)日：2024-09-12

申请号：US18406166

申请日：2024-01-07

Applicant: Sarfaraz K. Niazi ,  Matthias Magoola ,  Zafeer Ahmad

Inventor： Sarfaraz K. Niazi ,  Matthias Magoola ,  Zafeer Ahmad

IPC: A61K31/7105 ,  A61K9/51 ,  A61K39/00

CPC classification number: A61K31/7105 ,  A61K9/5123 ,  A61K2039/53 ,  A61K2039/55555 ,  C12N2830/50

Abstract: TNF-alpha (Tumor Necrosis Factor-alpha) is a cytokine, a protein involved in the inflammation process in the body. It plays a crucial role in the immune system, primarily produced by activated macrophages the white blood cells. TNF-alpha is critical in the inflammatory response to infections and diseases, but it can also contribute to inflammatory and autoimmune diseases when produced in excess. Many antibodies are created to inhibit over-expressed TNF-alpha but with serious side effects. The present invention provides a mRNA vaccine to reduce the titer of TNF-alpha, leading to treating multiple life-threatening diseases including but not limited to rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis, plaque psoriasis, inflammatory bowel disease, type 2 diabetes, tumor progression, angiogenesis, and metastasis, heart failure from myocardial cell death, and atherosclerosis from fibrosis.

公开(公告)号：US20240207303A1

公开(公告)日：2024-06-27

申请号：US18503559

申请日：2023-11-07

Applicant: Sarfaraz K. Niazi ,  Matthias Magoola

Inventor： Sarfaraz K. Niazi ,  Matthias Magoola

IPC: A61K31/7105 ,  A61K9/51 ,  A61K38/48 ,  C12N15/88

CPC classification number: A61K31/7105 ,  A61K9/5192 ,  A61K38/4893 ,  C12N15/88

Abstract: The present invention relates to a composition for expressing botulinum toxin in target tissue by injecting or topically applying an mRNA product capable of expressing the toxin.

公开(公告)号：US20240293519A1

公开(公告)日：2024-09-05

申请号：US18403377

申请日：2024-01-03

Applicant: Sarfaraz K. Niazi ,  Matthias Magoola ,  Zafeer Ahmad

Inventor： Sarfaraz K. Niazi ,  Matthias Magoola ,  Zafeer Ahmad

IPC: A61K39/00

CPC classification number: A61K39/0007 ,  A61K2039/53 ,  A61K2039/70

Abstract: mRNA coding vaccines to treat neurodegenerative disorders (NDs), particularly Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS), Corticobasal Degeneration (CBD), Frontotemporal Dementia (FTD), Lewy Body Dementia (LBD), Multiple System Atrophy (MSA), Parkinson's Disease Dementia (PSD), and Progressive Supranuclear Palsy (PSP), to scavenge improperly folded or aggregated proteins 2MXU (PDB) (Aβ42), P10636 TAU_HUMAN (Tau Protein), P37840·SYUA_HUMAN (α-Synuclein), Q13148.TADBP_HUMAN (TDP-43), and P35637·FUS_HUMAN by generating specific antibodies based on the epitopes of these proteins. The epitopes can be linked to generate the open reading frames of mRNA vaccines.

公开(公告)号：US20240285742A1

公开(公告)日：2024-08-29

申请号：US18398119

申请日：2023-12-27

Applicant: Sarfaraz K. Niazi ,  Matthias Magoola ,  Zafeer Ahmad

Inventor： Sarfaraz K. Niazi ,  Matthias Magoola ,  Zafeer Ahmad

IPC: A61K39/015 ,  A61K39/00

CPC classification number: A61K39/015 ,  A61K2039/53 ,  A61K2039/55555 ,  A61K2039/572 ,  A61K2039/575 ,  C12N2310/532

Abstract: An mRNA composition for malaria prevention and treatment comprising a coding mRNA capable of expressing proteins and peptides of malaria pathogens, coming from linear epitopes and protein structure of antigens.

公开(公告)号：US20250043258A1

公开(公告)日：2025-02-06

申请号：US18496845

申请日：2023-10-28

Applicant: Sarfaraz K. Niazi ,  Matthias Magoola

Inventor： Sarfaraz K. Niazi ,  Matthias Magoola

IPC: C12N9/22 ,  A61K31/502 ,  A61K31/519 ,  A61K31/522 ,  A61K31/5386 ,  A61K31/551 ,  A61K31/7088 ,  A61K38/46 ,  C12N15/11 ,  C12N15/88

Abstract: A novel composition for treating cancer comprising of a gRNA-Cas9 complex capable of locating, binding, and causing a double-strand break of the gene that is prevented from repair by accompanying DNA repair inhibitors.

公开(公告)号：US20240277753A1

公开(公告)日：2024-08-22

申请号：US18414141

申请日：2024-01-16

Applicant: Sarfaraz K. Niazi ,  Matthias Magoola ,  Zafeer Ahmad

Inventor： Sarfaraz K. Niazi ,  Matthias Magoola ,  Zafeer Ahmad

IPC: A61K31/711 ,  A61K9/127 ,  A61K9/51 ,  C07K14/505

CPC classification number: A61K31/711 ,  A61K9/1272 ,  A61K9/5123 ,  C07K14/505

Abstract: Darbepoetin alpha treats anemia and it is traditionally manufactured using recombinant Chinese Hamster Ovary cells, a complex and expensive process; this invention reports an mRNA composition that encodes darbepoetin alpha in vivo as a therapeutic protein.

公开(公告)号：US20240269260A1

公开(公告)日：2024-08-15

申请号：US18501992

申请日：2023-11-04

Applicant: Sarfaraz K. Niazi ,  Matthias Magoola

Inventor： Sarfaraz K. Niazi ,  Matthias Magoola

IPC: A61K39/21 ,  A61K39/00 ,  C12N7/00

CPC classification number: A61K39/21 ,  C12N7/00 ,  A61K2039/53 ,  A61K2039/55555 ,  C12N2710/00022 ,  C12N2710/20034 ,  C12N2740/16022 ,  C12N2740/16034

Abstract: The present invention generally relates to the field of molecular biology and immunology; more specifically, the invention relates to a messenger RNA (mRNA) composition to express selected epitopes of the antigens of Human Immunodeficiency Virus (HIV) and Human Papillomavirus (HPV) for inducing an immune response to prevent or treat HIV and HPV infections.